Viking outlines ~$100M average quarterly cash usage as Phase III SUNRISE and VANQUISH advance

Earnings Call Insights: Viking Therapeutics (VKTX) Q3 2026

Management View

"During the third quarter, we made important progress across multiple pipeline programs and announced positive results from an innovative maintenance dosing study in our obesity program," said President, CEO & Director Brian Lian.

Source: Seeking Alpha Tech